Torna alla classifica

Thermo Fisher Scientific Inc (TMO)

Sopravvalutato
HealthcareDiagnostics & ResearchUnited States

Fondamentale

61

Prezzo

$660.82

Capitalizzazione

$250.91B

Parte 1 · Quanto vale l'azienda

Panoramica

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Per questa società non c'è ancora una scheda redazionale

Concorrenti diretti

Con chi questa società si contende gli stessi clienti

Per questa società non c'è ancora una scheda redazionale

Per questa società non c'è ancora un elenco di concorrenti.

Stato Patrimoniale e Liquidità

Ricavi

$46.34B

Ultimi 12 mesi (al 27/06/2026)

Utile Netto

$6.97B

Ultimi 12 mesi (al 27/06/2026)

Free Cash Flow

$6.29B

Patrimonio Netto Totale

$53.41B

Passività Totali

$56.93B

Rapporto di Liquidità

1.55

Copertura Interessi

5.46

Debito/EBITDA

3.62

Utile per Azione

Ricavi e Utile Netto

Free Cash Flow

Scomposizione Ricavi

Prospetto storico

Margini nel tempo

Il debito nel tempo

Quanto pesa il debito

Griglia della crescita

Crescita — Ricavi

Stima del Fair Value

Caso generaleSopravvalutato

Fair Value

$437.42

Prezzo Attuale

$660.82

Margine di Sicurezza

-51.1%

Range Fair Value

$284.32 - $590.52

Intervallo di dispersione tra i metodi di valutazione usati, non una stima statisticamente calibrata.

Metodi di Stima

Target degli analisti:$653.11
Flussi di cassa scontati (DCF):$291.26
Multiplo sugli utili (P/E):$455.96
Formula di Graham:$207.75
Valore della capacità di reddito (EPV):$187.20
P/B giustificato:$251.52
Sconto dei dividendi (Gordon):$33.18
P/FFO, i fondi da operazioni:Dati insufficienti per calcolarlo
Utili di mezzo ciclo:$349.15
Multiplo sui ricavi:$492.07
Consenso Analisti:Strong Buy (29B / 7H / 0S)
Ultima Sorpresa Utili:+4.54%

Metriche di Valutazione

Rapporto P/E

36.31

ROE

12.6%

Rapporto P/B

4.74

P/FCF

34.11

Margine Lordo

-

ROIC

6.6%

Radar Redditività

Creazione di Valore (Vantaggio Competitivo)

ROIC

6.6%

WACC

8.3%

ROIC − WACC

-1.7 pp

Il ROIC è sotto il costo del capitale: l'azienda distrugge valore per ogni dollaro investito.

Criteri di Analisi Fondamentale

Superati (19)

  • EPS shows upward trend
  • EPS CAGR 13.95%
  • Price CAGR 15.76%
  • ROIC 6.6%
  • Debt/Equity ratio
  • Operating Margin 17.6%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 13.3%
  • Revenue Growth 5Y 6.7%
  • Analyst Consensus 81% Buy
  • Earnings Surprise avg 3.2%
  • Earnings Quality (OCF/NI) 1.29
  • Share Dilution -1.4%
  • Piotroski F-Score 5/9

Non superati (7)

  • P/FCF 34.11
  • P/B Ratio 4.74
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • PEG Ratio 16.99
  • Net Margin Trend 15.0% vs 15.2%

Non disponibili (2)

  • Gross Margin NaN%
  • Dividend Payout NaN%

Piotroski F-Score

5/9

Segnali misti: alcune aree necessitano attenzione

score
criteria

Qualità degli Utili

1.29

Alta qualità: utili supportati da cash

Diluizione Azionaria

-1.4%

Riacquisto azioni. Favorevole agli azionisti

Partecipazioni istituzionali

Governance

Team Dirigenziale

NomeRuoloEtà
Mr. Marc N. CasperChairman & CEO57
Mr. Gianluca PettitiPresident, COO & President of Products and Technologies46
Mr. James R. MeyerSenior VP & CFO45
Mr. Joseph R. HolmesVP & Chief Accounting Officer45
Mr. Ryan J. SnyderSenior VP & Chief Information Officer-
Dr. Karen E. Nelson Ph.D.Chief Scientific Officer-
Mr. Rafael TejadaVice President of Investor Relations-
Mr. Thomas Bailey Shropshire Jr.Senior VP and General Counsel-
Ms. Sandy B. PoundVP & Chief Communications Officer-
Mr. Alan J. MalusSenior Vice President of Strategy & Corporate Development65

Rischio Audit

2

Rischio CdA

7

Rischio Compensi

10

Rischio Diritti Azionisti

1

Parte 2 · Il prezzo e il momento d'ingresso

Questa parte non serve a capire se l'azienda vale: serve a scegliere quando comprarla, dopo che i fondamentali ti hanno convinto. Dentro: analisi tecnica, potenziale, drawdown storici, esposizione gamma.

Documenti

  • Relazione annuale (10-K)

    Una panoramica annuale del business, dei risultati finanziari e dei rischi dell'azienda.

    Depositato il 2026-02-26

    Vedi documento
  • Relazione trimestrale (10-Q)

    Un aggiornamento sull'andamento finanziario degli ultimi tre mesi.

    Depositato il 2026-07-31

    Vedi documento
  • Comunicazione price-sensitive (8-K)

    Una comunicazione su un evento importante, come un cambio ai vertici o un grande annuncio.

    Depositato il 2026-07-23

    Vedi documento

via SEC EDGAR

Storico Ricavi

via SEC EDGAR

Ultime Notizie

Ultime notizie per TMO, da Markets Gazette.

  • 5/25/2026POSITIVE
    If You Invested $1000 In Thermo Fisher Scientific Stock 20 Years Ago, You Would Have This Much Today

    An investment of $1000 in Thermo Fisher Scientific (TMO) stock 20 years ago would have yielded a substantial return, illustrating the company's long-term growth trajectory. While the exact final value is not provided in this snippet, historical performance data suggests significant capital appreciation. This underscores Thermo Fisher's consistent operational success and market leadership in the life sciences and diagnostics sectors. Investors considering TMO should note its history of innovation and strategic acquisitions, which have contributed to its robust financial performance and shareholder value creation over the past two decades.

  • 3/12/2026POSITIVE
    Here's How Much $100 Invested In Thermo Fisher Scientific 15 Years Ago Would Be Worth Today

    An investment of $100 in Thermo Fisher Scientific (TMO) 15 years ago would have grown to approximately $1,040 today, representing a substantial 940% return. This performance significantly outpaced the broader market during the same period. The company's consistent growth trajectory, driven by its diversified portfolio in life sciences, diagnostics, and laboratory products, has been a key factor in its stock's appreciation. Investors who held TMO stock have benefited from its strong operational execution and strategic acquisitions, underscoring its resilience and long-term value creation potential.

  • 3/2/2026NEUTRAL
    Here's How Much $100 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth Today

    A retrospective analysis highlights the remarkable performance of Thermo Fisher Scientific, revealing how a $100 investment made two decades ago would have generated substantial returns for today's investors. While this study doesn't provide direct future guidance, it underscores the company's ability to create long-term value, driven by its leadership in life sciences, diagnostics, and research. Consistent growth and innovation have allowed Thermo Fisher to solidify its market position, transforming a modest initial capital into a significantly larger sum. For investors, this serves as a reminder of the importance of patience and selecting companies with strong fundamentals and a lasting competitive advantage.

via Markets Gazette